Normal B-cell ranges in infants: A systematic review and meta-analysis - 03/11/22
, Lisa Law, MSc c, Kim Rand, PhD d, Catarina Raposo, PhD b, Wei Wei, PhD e, Licinio Craveiro, MD, PhD b, Tobias Derfuss, MD fAbstract |
Background |
During the first year of life, B-cell level is a valuable indicator of whether external factors, such as exposure to B-cell–depleting therapies, have an adverse impact on immune system development. However, there are no standard reference ranges of B-cell levels in healthy infants by age.
Objective |
Our aim was to estimate the normal range of B-cell levels in infants, by age, during the first year of life by pooling data from published studies.
Methods |
Studies reporting B-cell levels measured by using flow cytometry and CD19 markers in healthy infants were identified via a systematic literature review. Quality and feasibility assessments determined suitability for inclusion in meta-analyses by age group and/or continuous age. Means and normal ranges (2.5th-97.5th percentile) were estimated for absolute and percentage B-cell levels. Sensitivity analyses assessed the impact of various assumptions.
Results |
Of the 37 relevant studies identified, 28 were included in at least 1 meta-analysis. The means and normal ranges of B-cell levels were found to be 707 cells/μL in cord blood (range 123-2324 cells/μL), 508 cells/μL in infants aged 0 to 1 month (range 132-1369 cells/μL), 1493 cells/μL in infants aged 1 to 6 months (range 416-3877 cells/μL), and 1474 cells/μL in infants older than 6 months (range 416-3805 cells/μL). The continuous age model showed that B-cell levels peaked at week 26. Trends were similar for the percentage B-cell estimates and in sensitivity analyses.
Conclusion |
These meta-analyses provide the first normal reference ranges for B-cell levels in infants, by week of age, during the first year of life.
Le texte complet de cet article est disponible en PDF.Key words : B cell, CD19, flow cytometry, normal range, reference range, lower limit of normal, newborns, infants, cord blood
Abbreviations used : MBC, PC, SLR
Plan
| Supported by F. Hoffmann-La Roche Ltd. Employees of F. Hoffmann-La Roche Ltd contributed to the study design, interpretation of data, review of the writing of the report, and the decision to submit the article for publication. |
|
| Disclosure of potential conflict of interest: F. Borriello was employed by Boston Children’s Hospital at the time of the study and received personal compensation for consulting from MSD (a subsidiary of Merck and Co) and F. Hoffmann-La Roche Ltd. N. Pasquarelli, C. Raposo, and L. Craveiro are employees and shareholders of F. Hoffmann-La Roche Ltd. W. Wei was an employee of F. Hoffmann-La Roche Ltd at the time of the study. L. Law is an employee of Oxford PharmaGenesis, which has received funding from F. Hoffmann-La Roche Ltd to perform the systematic literature review and medical writing of this article in accordance with Good Publications Practice 3 (GPP3) guidelines (gpp3). K. Rand is an employee of Maths in Health, which has received funding from F. Hoffmann-La Roche Ltd to perform the statistical analyses of this study. The remaining author declares that he has no relevant conflicts of interest. |
Vol 150 - N° 5
P. 1216-1224 - novembre 2022 Retour au numéro
Article précédent
- Farm living and allergic rhinitis from childhood to young adulthood: Prospective results of the GABRIEL study
- Sonja Strieker, Tobias Weinmann, Jessica Gerlich, Erika von Mutius, Dennis Nowak, Katja Radon, Laura Wengenroth
- Differential mast cell mediators in systemic mastocytosis and hereditary α-tryptasemia
- Matthew P. Giannetti, Grace Godwin, Emily Weller, Joseph H. Butterfield, Mariana Castells
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?